Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients

This international Phase II study is comparing two treatment approaches for advanced liver cancer (HCC) that cannot be surgically removed: a targeted internal radiation treatment (called Y-90 SIRT, which delivers radiation beads directly to the liver tumor) followed by either an immunotherapy combination (atezolizumab + bevacizumab) or a placebo. **You may be eligible if...** - You have been diagnosed with liver cancer (HCC) that is confined to the liver but is large or has grown into nearby blood vessels - You have not received prior systemic (whole-body) treatment for HCC - Your liver is functioning adequately (Child-Pugh A or B7) - You have a decent overall health status **You may NOT be eligible if...** - Your liver cancer has spread outside the liver - You have had prior systemic cancer therapy for HCC - You have autoimmune conditions or certain liver conditions that would make immunotherapy unsafe - Your liver function is significantly impaired Talk to your doctor to see if this trial is right for you.